Autologous stem cells for personalised medicine

New Biotechnology

Volumn 29, Issue 6, 2012, Pages 641-650

  Prasongchean, Weerapong ^a   Ferretti, Patrizia ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS CELL; CELL BASED THERAPIES; CELL SOURCES; CLINICAL PRACTICES; CLINICAL TRIAL; DIFFERENTIATED CELLS; ETHICAL ISSUES; HUMAN DISEASE; PERSONALISED MEDICINES; PLURIPOTENT; POTENTIAL APPLICATIONS; REGENERATIVE MEDICINE; REGULATORY ISSUES; STEM CELL BIOLOGY; TISSUE REPAIR;

CYTOLOGY; DISEASE CONTROL; HUMAN ENGINEERING; PHILOSOPHICAL ASPECTS; TISSUE;

STEM CELLS;

ADIPOSE TISSUE DERIVED STEM CELL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CELL DIFFERENTIATION; CLINICAL PRACTICE; CORD BLOOD STEM CELL TRANSPLANTATION; EMBRYONIC STEM CELL; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; HOMEOSTASIS; HUMAN; IN VITRO STUDY; LIMBAL STEM CELL TRANSPLANTATION; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; PATIENT SAFETY; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; POPULATION; PRIORITY JOURNAL; REGENERATIVE MEDICINE; SOMATIC STEM CELL; STEM CELL; TISSUE REGENERATION; TISSUE REPAIR;

HUMANS; INDIVIDUALIZED MEDICINE; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSPLANTATION, AUTOLOGOUS; WOUND HEALING;

EID: 84865411112     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2012.04.002     Document Type: Article

References (140)

1. Ichim T., et al. The king is dead, long live the king: entering a new era of stem cell research and clinical development. J. Transl. Med. 2011, 9:218.
2. Smith D. Commercialization challenges associated with induced pluripotent stem cell-based products. Regen. Med. 2010, 5:593-603.
3. Evans M.J., Kaufman M.H. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981, 292:154-156.
4. Martin G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:7634-7638.
5. Thomson J.A., et al. Isolation of a primate embryonic stem cell line. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7844-7848.
6. Thomson J.A., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
7. Ben-David U., Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer 2011, 11:268-277.
8. Bonde S., Zavazava N. Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients. Stem Cells 2006, 24:2192-2201.
9. Knoepfler P.S. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 2009, 27:1050-1056.
10. Swijnenburg R.J., et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005, 112:I166-I172.
11. Ghosh Z., et al. Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. Cancer Res. 2011, 71:5030-5039.
12. Hug K., Hermeren G. Do we still need human embryonic stem cells for stem cell-based therapies? Epistemic and ethical aspects. Stem Cell Rev. 2011.
13. Condic M.L., Rao M. Regulatory issues for personalized pluripotent cells. Stem Cells 2008, 26:2753-2758.
14. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
15. Grskovic M., et al. Induced pluripotent stem cells - opportunities for disease modelling and drug discovery. Nat. Rev. Drug Discov. 2011.
16. Sanai N., et al. Corridors of migrating neurons in the human brain and their decline during infancy. Nature 2011, 478:382-386.
17. Li L., Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010, 327:542-545.
18. Moore K.A., Lemischka I.R. Stem cells and their niches. Science 2006, 311:1880-1885.
19. Tanaka E.M., Ferretti P. Considering the evolution of regeneration in the central nervous system. Nat. Rev. Neurosci. 2009, 10:713-723.
20. Ferretti P. Is there a relationship between adult neurogenesis and neuron generation following injury across evolution. Eur. J. Neurosci. 2011, 34:951-962.
21. Chai Y., Maxson R.E. Recent advances in craniofacial morphogenesis. Dev. Dyn. 2006, 235:2353-2375.
22. Yildirim S., et al. Tooth regeneration: a revolution in stomatology and evolution in regenerative medicine. Int. J. Oral Sci. 2011, 3:107-116.
23. Steinhauser M.L., Lee R.T. Regeneration of the heart. EMBO Mol. Med. 2011.
24. Graham R.M., Harvey R.P. The ontogeny of cardiac regeneration. Circ. Res. 2011, 108:1304-1305.
25. Till J.E., Mc C.E. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res. 1961, 14:213-222.
26. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978, 4:7-25.
27. Armitage J.O. Bone marrow transplantation. N. Engl. J. Med. 1994, 330:827-838.
28. Elfenbein G.J. Granulocyte-colony stimulating factor primed bone marrow and granulocyte-colony stimulating factor mobilized peripheral blood stem cells are equivalent for engraftment: which to choose?. Pediatr. Transplant 2005, 9(Suppl. 7):37-47.
29. Maximow A.A. Relation of blood cells to connective tissues and endothelium. Physiol. Rev. 1924, 4:533-563.
30. Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood 2004, 103:1580-1585.
31. Vose J.M., et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk. Lymphoma 2009, 50:1412-1421.
32. Novitzky N., et al. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis. Biol. Blood Marrow Transplant 2011, 17:875-884.
33. Ram R., et al. Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer 2010, 116:3447-3457.
34. Willemze R., Labar B. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation. Seminars Hematol. 2007, 44:267-273.
35. Gaspar H.B., et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med. 2011, 3:97ra80.
36. Hacein-Bey-Abina S., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 2002, 346:1185-1193.
37. Magnus D. Translating stem cell research: challenges at the research frontier. J. Law Med. Ethics 2010, Summer:267-276.
38. Celia Witten A.B., et al. Overview of FDA regulatory process. Principles of Regenerative Medicines 2008, Academic Press. R.L. Anthony Atala, J.T. Robert Nerem (Eds.).
39. Schneider C.K., et al. Challenges with advanced therapy medicinal products and how to meet them. Nat. Rev. Drug Discov. 2010, 9:195-201.
40. Vanlauwe J., et al. Five-year outcome of characterized chondrocyte implantation versus microfracture for symptomatic cartilage defects of the knee: early treatment matters. Am. J. Sports Med. 2011.
41. MacLaren R.E., et al. Retinal repair by transplantation of photoreceptor precursors. Nature 2006, 444:203-207.
42. Kriks S., et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011.
43. Janssens S.P. Cardiac bone marrow cell therapy: the proof of the pudding remains in the eating. Eur. Heart J. 2011, 32:1697-1700.
44. Choi Y.H., et al. Mesenchymal stem cells for cardiac cell therapy. Hum. Gene Ther. 2011, 22:3-17.
45. Bolli R., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011.
46. Leclerc T., et al. Cell therapy of burns. Cell Prolif. 2011, 44(Suppl. 1):48-54.
47. Fu X., Li H. Mesenchymal stem cells and skin wound repair and regeneration: possibilities and questions. Cell Tissue Res. 2009, 335:317-321.
48. Ibrahim A.G., et al. Restoration of hand function in a rat model of repair of brachial plexus injury. Brain 2009, 132:1268-1276.
49. Li Y., et al. Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells. Science 1997, 277:2000-2002.
50. Ramon-Cueto A., et al. Long-distance axonal regeneration in the transected adult rat spinal cord is promoted by olfactory ensheathing glia transplants. J. Neurosci. 1998, 18:3803-3815.
51. Takeoka A., et al. Axon regeneration can facilitate or suppress hindlimb function after olfactory ensheathing glia transplantation. J. Neurosci. 2011, 31:4298-4310.
52. Feron F., et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 2005, 128:2951-2960.
53. Mackay-Sim A., St John J.A. Olfactory ensheathing cells from the nose: clinical application in human spinal cord injuries. Exp. Neurol. 2011, 229:174-180.
54. Ramon-Cueto A., Munoz-Quiles C. Clinical application of adult olfactory bulb ensheathing glia for nervous system repair. Exp. Neurol. 2011, 229:181-194.
55. Bernardo M.E., et al. Mesenchymal stromal cells. Ann. N. Y. Acad. Sci. 2009, 1176:101-117.
56. Prasongchean W., et al. Amniotic fluid stem cells increase embryo survival following injury. Stem Cells Dev. 2011.
57. Trounson A., et al. Clinical trials for stem cell therapies. BMC Med. 2011, 9:52.
58. Grellier M., et al. The effect of the co-immobilization of human osteoprogenitors and endothelial cells within alginate microspheres on mineralization in a bone defect. Biomaterials 2009, 30:3271-3278.
59. Santos-Ruiz L., et al. Potential use of craniosynostotic osteoprogenitors and bioactive scaffolds for bone engineering. J. Tissue Eng. Regen. Med. 2007, 1:199-210.
60. Pappa K.I., Anagnou N.P. Novel sources of fetal stem cells: where do they fit on the developmental continuum. Regen. Med. 2009, 4:423-433.
61. Weber B., et al. Prenatally harvested cells for cardiovascular tissue engineering: fabrication of autologous implants prior to birth. Placenta 2011, 32(Suppl. 4):S316-S319.
62. Brunstein C.G., et al. Expanding the role of umbilical cord blood transplantation. Br. J. Haematol. 2007, 137:20-35.
63. Gluckman E., et al. Milestones in umbilical cord blood transplantation. Br. J. Haematol. 2011, 154:441-447.
64. Welte K., et al. International exchange of cord blood units: the registry aspects. Bone Marrow Transplant. 2010, 45:825-831.
65. Querol S., et al. Quality rather than quantity: the cord blood bank dilemma. Bone Marrow Transplant. 2010, 45:970-978.
66. Querol S., et al. The placental blood program of the Barcelona Cord Blood Bank. Bone Marrow Transplant. 1998, 22(Suppl. 1):S3-S5.
67. Rubinstein P. Cord blood banking for clinical transplantation. Bone Marrow Transplant. 2009, 44:635-642.
68. Kucia M., et al. Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood: preliminary report. Leukemia 2007, 21:297-303.
69. Zuba-Surma E.K., et al. Optimization of isolation and further characterization of umbilical-cord-blood-derived very small embryonic/epiblast-like stem cells (VSELs). Eur. J. Haematol. 2010, 84:34-46.
70. Bhartiya D., et al. Very small embryonic-like stem cells with maximum regenerative potential get discarded during cord blood banking and bone marrow processing for autologous stem cell therapy. Stem Cells Dev. 2011.
71. Sarkar S., et al. Neural origin of cells in amniotic fluid. Am. J. Obstet. Gynecol. 1980, 136:67-72.
72. Gosden C.M. Amniotic fluid cell types and culture. Br. Med. Bull. 1983, 39:348-354.
73. Tsangaris G., et al. The amniotic fluid cell proteome. Electrophoresis 2005, 26:1168-1173.
74. Prusa A.R., et al. Oct-4-expressing cells in human amniotic fluid: a new source for stem cell research. Hum. Reprod. 2003, 18:1489-1493.
75. Prusa A.R., et al. Neurogenic cells in human amniotic fluid. Am. J. Obstet. Gynecol. 2004, 191:309-314.
76. Stefanidis K., et al. Oxytocin receptor- and Oct-4-expressing cells in human amniotic fluid. Gynecol. Endocrinol. 2008, 24:280-284.
77. Shaw S.W., et al. Clinical applications of prenatal and postnatal therapy using stem cells retrieved from amniotic fluid. Curr. Opin. Obstet. Gynecol. 2011, 23:109-116.
78. De Coppi P., et al. Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 2007, 25:100-106.
79. Kolambkar Y.M., et al. Chondrogenic differentiation of amniotic fluid-derived stem cells. J. Mol. Histol. 2007, 38:405-413.
80. Kim J., et al. Human amniotic fluid-derived stem cells have characteristics of multipotent stem cells. Cell Prolif. 2007, 40:75-90.
81. Gekas J., et al. In vitro and in vivo study of human amniotic fluid-derived stem cell differentiation into myogenic lineage. Clin. Exp. Med. 2010, 10:1-6.
82. Shaw S.W., et al. Autologous transplantation of amniotic fluid-derived mesenchymal stem cells into sheep fetuses. Cell Transplant. 2011, 20:1015-1031.
83. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997, 276:71-74.
84. Pittenger M.F., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
85. Lee K.D., et al. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 2004, 40:1275-1284.
86. Xie Q.P., et al. Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. Differentiation 2009, 77:483-491.
87. Tian H., et al. Differentiation of human bone marrow mesenchymal stem cells into bladder cells: potential for urological tissue engineering. Tissue Eng. Part A 2010, 16:1769-1779.
88. Chun-mao H., et al. Human bone marrow-derived mesenchymal stem cells differentiate into epidermal-like cells in vitro. Differentiation 2007, 75:292-298.
89. Alexanian A.R. An efficient method for generation of neural-like cells from adult human bone marrow-derived mesenchymal stem cells. Regen. Med. 2010, 5:891-900.
90. Choong P.F., et al. Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro. Cytotherapy 2007, 9:170-183.
91. Kemp K., et al. Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival. J. Neurochem. 2010, 114:1569-1580.
92. Pati S., et al. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PLoS One 2011, 6:e25171.
93. Wu Y., et al. Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells 2010, 28:905-915.
94. Falanga V., et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng. 2007, 13:1299-1312.
95. Ravari H., et al. Treatment of non-healing wounds with autologous bone marrow cells, platelets, fibrin glue and collagen matrix. Cytotherapy 2011, 13:705-711.
96. Wakitani S., et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J. Tissue Eng. Regen. Med. 2011, 5:146-150.
97. Matsumoto T., et al. Articular cartilage repair with autologous bone marrow mesenchymal cells. J. Cell Physiol. 2010, 225:291-295.
98. Wen Y., et al. Direct autologous bone marrow-derived stem cell transplantation for ischemic heart disease: a meta-analysis. Exp. Opin. Biol. Ther. 2011, 11:559-567.
99. Suarez-Monteagudo C., et al. Autologous bone marrow stem cell neurotransplantation in stroke patients. An open study. Restor. Neurol. Neurosci. 2009, 27:151-161.
100. Venkataramana N.K., et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl. Res. 2010, 155:62-70.
101. Peer L.A. The neglected free fat graft, its behavior and clinical use. Am. J. Surg. 1956, 92:40-47.
102. Coleman S.R. Hand rejuvenation with structural fat grafting. Plast. Reconstr. Surg. 2002, 110:1731-1744. discussion 45-7.
103. Coleman S.R. Long-term survival of fat transplants: controlled demonstrations. Aesthetic Plast. Surg. 1995, 19:421-425.
104. Coleman S.R. Facial augmentation with structural fat grafting. Clin. Plast. Surg. 2006, 33:567-577.
105. Horl Hw Fau-Feller AM, et al. Technique for liposuction fat reimplantation and long-term volume evaluation by magnetic resonance imaging. 1991.
106. Tiryaki T., et al. Staged stem cell-enriched tissue (SET) injections for soft tissue augmentation in hostile recipient areas: a preliminary report. Aesthetic Plast. Surg. 2011.
107. Thanik V.D., et al. A murine model for studying diffusely injected human fat. Plast. Reconstr. Surg. 2009, 124:74-81.
108. Iyengar P., et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 2003, 22:6408-6423.
109. Muehlberg F.L., et al. Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis 2009, 30:589-597.
110. Guasti L., et al. High plasticity of paediatric adipose tissue-derived stem cells: too much for selective skeletogenic differentiation?. Stem Cells Transl Med 2012, in press.
111. Mosna F., et al. Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells Dev. 2010, 19:1449-1470.
112. Pachon-Pena G., et al. Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. J. Cell Physiol. 2011, 226:843-851.
113. Zuk P.A., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001, 7:211-228.
114. Kim M.H., et al. The effect of VEGF on the myogenic differentiation of adipose tissue derived stem cells within thermosensitive hydrogel matrices. Biomaterials 2010, 31:1213-1218.
115. Rodriguez L.V., et al. Clonogenic multipotent stem cells in human adipose tissue differentiate into functional smooth muscle cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12167-12172.
116. Choi Y.S., et al. Differentiation of human adipose-derived stem cells into beating cardiomyocytes. J. Cell Mol. Med. 2010, 14:878-889.
117. Ashjian P.H., et al. In vitro differentiation of human processed lipoaspirate cells into early neural progenitors. Plast. Reconstr. Surg. 2003, 111:1922-1931.
118. Kang S.K., et al. Neurogenesis of Rhesus adipose stromal cells. J. Cell Sci. 2004, 117:4289-4299.
119. Zavan B., et al. Neural potential of a stem cell population in the adipose and cutaneous tissues. Neurol. Res. 2010, 32:47-54.
120. Banas A., et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 2007, 46:219-228.
121. Auxenfans C., et al. Adipose-derived stem cells (ASCs) as a source of endothelial cells in the reconstruction of endothelialized skin equivalents. J. Tissue Eng. Regen. Med. 2011.
122. Zimmerlin L., et al. Stromal vascular progenitors in adult human adipose tissue. Cytometry A 2010, 77:22-30.
123. Ii M., et al. Synergistic effect of adipose-derived stem cell therapy and bone marrow progenitor recruitment in ischemic heart. Lab Invest. 2011, 91:539-552.
124. Mesimaki K., et al. Novel maxillary reconstruction with ectopic bone formation by GMP adipose stem cells. Int. J. Oral Maxillofac. Surg. 2009, 38:201-209.
125. Ra J.C., et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011, 20:1297-1308.
126. Shoji T., et al. Local transplantation of human multipotent adipose-derived stem cells accelerates fracture healing via enhanced osteogenesis and angiogenesis. Lab Invest. 2010, 90:637-649.
127. Notara M., et al. In sickness and in health: Corneal epithelial stem cell biology, pathology and therapy. Exp. Eye Res. 2010, 90:188-195.
128. Baylis O., et al. 13 years of cultured limbal epithelial cell therapy: a review of the outcomes. J. Cell Biochem. 2011, 112:993-1002.
129. Rama P., et al. Limbal stem-cell therapy and long-term corneal regeneration. N. Engl. J. Med. 2010, 363:147-155.
130. Satake Y., et al. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. Ophthalmology 2011, 118:1524-1530.
131. Nakamura T., et al. Long-term results of autologous cultivated oral mucosal epithelial transplantation in the scar phase of severe ocular surface disorders. Br. J. Ophthalmol. 2011, 95:942-946.
132. Nishida K., et al. Corneal reconstruction with tissue-engineered cell sheets composed of autologous oral mucosal epithelium. N. Engl. J. Med. 2004, 351:1187-1196.
133. Kolli S., et al. Successful clinical implementation of corneal epithelial stem cell therapy for treatment of unilateral limbal stem cell deficiency. Stem Cells 2010, 28:597-610.
134. O'Callaghan A.R., Daniels J.T. Concise review: limbal epithelial stem cell therapy: controversies and challenges. Stem Cells 2011, 29:1923-1932.
135. Brundin P., et al. Neural grafting in Parkinson's disease Problems and possibilities. Prog. Brain Res. 2010, 184:265-294.
136. Brands K., et al. Reduced immunogenicity of first-trimester human fetal pancreas. Diabetes 2008, 57:627-634.
137. Moseley B.D., et al. Neurological picture Contralateral cutaneous and MRI findings in a patient with Parry-Romberg syndrome. J. Neurol. Neurosurg. Psychiatry 2010, 81:1400-1401.
138. Lazaridou E., et al. Parry-Romberg syndrome. J. Dermatol. Case Rep. 2010, 4:30-32.
139. Viana M., et al. Trigeminal neuropathic pain in a patient with progressive facial hemiatrophy (parry-romberg syndrome). Arch. Neurol. 2011, 68:938-943.
140. Sterodimas A., et al. Autologous fat transplantation for the treatment of Parry-Romberg syndrome. J. Plast. Reconstr. Aesthet. Surg. 2009, 62:e424-e426.